3 Small-Cap Healthcare Stocks with More Than 45% Upside, According to Analysts
Alvotech ($ALVO), Zenas BioPharma, Inc. ($ZBIO), and Bioventus ($BVS) are three small-cap healthcare stocks that could offer more than 45% upside, ...
Zenas Biopharma Inc. (ZBIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 7,800,000 | $10,078,583 | 0.29% | ||
| 2. | SilverArc Capital Devesh Gandhi | 334,057 | $9,009,517 | -35% | 1.05% |
| 3. | 3,598,000 | $4,627,130 | -29% | 0.03% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 166,851 | $4,499,971 | -49% | 0% |
| 5. | Walleye Capital Will England | 119,551 | $3,224,290 | -43% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.88 | 60,000 | $1,012,800.00 | 96,928 | 2026-05-18 | Filing | |
| $17.62 | 35,000 | $616,700.00 | 1,786,039 | 2026-04-29 | Filing | |
| $18.02 | 25,000 | $450,500.00 | 1,751,039 | 2026-04-28 | Filing | |
| $18.63 | 3,768 | $70,197.84 | 426,736 | 2026-03-31 | Filing | |
| $20.00 | 150,000 | $3,000,000.00 | 2,359,025 | 2026-03-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,792,887 | $264,114,163 | 0.01% | |
| 2. | 3,332,718 | $89,883,404 | 0% | |
| 3. | 3,107,308 | $83,804,097 | 0.12% | |
| 4. | 2,925,343 | $78,896,501 | 0.02% | |
| 5. | 2,388,150 | $64,408,406 | 32.82% |
News See All
Can Zenas BioPharma's (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
When biotechnology innovators approach the commercialization cliff, market participants must weigh the clinical promise of a lead asset against the stark realities of surging operating expenses and capital...
12 Best IPO Stocks with Huge Upside Potential
In this article, we will discuss the 12 Best IPO Stocks with Huge Upside Potential.
Here’s Why Zenas BioPharma (ZBIO) Traded Lower in Q1
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter is available to download here.
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory
We came across a bullish thesis on Zenas BioPharma, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ZBIO.
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4
Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S.
Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation
Meridian Funds, managed by ArrowMark Partners, released its third-quarter 2025 investor letter for the “Meridian Small Cap Growth Fund.” A copy of the letter can be downloaded here.
Hedge Fund Resource Center